CX 4945
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medulloblastoma, Childhood
Conditions
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
Trial Timeline
Jul 25, 2019 → Aug 11, 2025
NCT ID
NCT03904862About CX 4945
CX 4945 is a phase 1/2 stage product being developed by Brain Biotech for Medulloblastoma, Childhood. The current trial status is terminated. This product is registered under clinical trial identifier NCT03904862. Target conditions include Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03904862 | Phase 1/2 | Terminated |
Competing Products
9 competing products in Medulloblastoma, Childhood
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2940680 + LY2940680 | Eli Lilly | Phase 1 | 33 |
| LDE225 + TMZ | Novartis | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1/2 | 41 |
| Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine | Brain Biotech | Phase 1 | 25 |
| Modified Measles Virus + Modified Measles Virus Lumbar Puncture | Brain Biotech | Phase 1 | 25 |
| SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years | Brain Biotech | Phase 1 | 25 |
| PEP-CMV | Brain Biotech | Phase 1 | 25 |
| Apatinib Combined With Temozolomide and Etoposide Capsules | Brain Biotech | Phase 2 | 44 |
| Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics | Brain Biotech | Phase 2 | 44 |